A shot in the arm for Biota

It may be a cliché that Australian scientists are good at science and poor at commercialising it, but there is substance to this. There is also substance to the view that Australian investors aren't good at understanding and valuing biotechnology. Both those issues are factors in the decision by Biota Holdings to merge with Nabi Biopharmaceuticals of the US and …